LOWELL, Mass.--(BUSINESS WIRE)--RevBio, Inc., announced that it has received approval from the U.S. Food and Drug Administration to start a 20-patient pilot clinical trial to examine the safety and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback